超越当前直接口服抗凝药的新型与实验性抗凝策略
本文综述了超越直接口服抗凝药(DOACs)的新型与实验性抗凝及纤溶/溶栓治疗的研究现状。重点讨论了接触通路抑制(FXIIa和FXIa抑制的体外、体内研究及临床试验)、共同通路靶点(FV、FVIII、FIX)抑制、纤维蛋白/纤维蛋白原及FXIII靶向治疗,以及利用天然抗凝通路和纤溶机制的治疗机会。文章总结了各机制的研究进展(是否从体外推进至体内实验、是否已开展临床试验),并评估了所选靶点的相对临床前和临床试验进展。
要点
- 接触通路(FXIIa/FXIa)抑制是新型抗凝策略的重要方向,已有体外、体内研究及临床试验探索。
- 共同通路靶点(FV、FVIII、FIX)抑制及纤维蛋白/纤维蛋白原、FXIII靶向治疗是潜在替代策略。
- 利用天然抗凝通路和纤溶机制的治疗机会正在被探索,有望改善安全性并减少血栓性疾病负担。
核心结论
- 对血栓形成机制的深入理解有望推动新型抗凝药的发展,在提高当前治疗安全性的同时减少血栓性疾病的影响和负担。
研究设计与样本
- 本文为综述,总结和讨论了超越DOACs的新型与实验性抗凝及纤溶/溶栓治疗的最新研究进展。
主要发现
- 综述涵盖了接触通路抑制(FXIIa和FXIa抑制的体外和体内研究及临床试验)的研究。
- 综述分析了共同通路凝血靶点(FV、FVIII和FIX)抑制的体外和体内研究。
- 综述分析了靶向纤维蛋白或纤维蛋白原以及FXIII的治疗选择。
- 综述探讨了利用天然抗凝通路和纤溶机制的治疗机会。
- 综述总结了各机制的最新研究状态,包括是否从体外推进至体内实验以及是否已开展临床试验,并评估了所选靶点的相对临床前和临床试验进展。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Thrombosis, when considering all its manifestations including myocardial infarction, stroke, and venous thromboembolism, constitutes the leading cause of death world-wide. Treatment of thrombotic diseases has been revolutionized by direct oral anticoagulants (DOACs) targeting thrombin and factor (F)Xa. However, the therapeutic or prophylactic use of DOACs is not without limitations, including persistent and significant bleeding risks. In this review, we summarize and discuss current state-of-the-art of novel and experimental anticoagulation and fibrinolytic/thrombolytic therapies beyond DOACs. In particular, we review studies investigating contact pathway inhibition, including in vitro and in vivo studies of FXIIa and FXIa inhibition, and clinical trials of contact pathway inhibition. We review in vitro and in vivo studies investigating inhibition of common pathway coagulation targets, including FV, FVIII, and FIX. This is followed by analysis of options for the therapeutic targeting of fibrin or fibrinogen and FXIII. Next, we explore opportunities for the therapeutic harnessing of naturally occurring anticoagulant pathways as well as fibrinolytic mechanisms. The current state-of-the-art research for each of these mechanisms is summarized, including whether studies have progressed from in vitro to in vivo experimentation and whether clinical trials have been performed. We highlight particularly novel areas of interest and include evaluation of the relative preclinical and clinical trial progress for the selected targets. The increased understanding of mechanisms driving thrombosis holds promise for future developments in novel anticoagulants that may contribute to reducing the impact and burden of thrombotic diseases while improving safety of current therapeutic options.
引用
- Dobbing HC, Webb KL, Ariëns RAS, et al. Novel and experimental anticoagulant strategies beyond current direct oral anticoagulants. J Thromb Haemost. 2026. PMID: 41485707. doi:10.1016/j.jtha.2025.11.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。